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zeem Latib, MB BCH,*‡ Luca Ferri, MD,* Alfonso Ielasi, MD,* Cosmo Godino, MD,*†
laide Chieffo, MD,* Valeria Magni, MD,* Giorgio Bassanelli, MD,*
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auro Carlino, MD,* Flavio Airoldi, MD,* Giuseppe M. Sangiorgi, MD,†
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bjectives The aim of this study was to evaluate the efﬁcacy and safety of unrestricted everolimus-
luting stent (EES) implantation in a contemporary cohort of real-world patients.
ackground The randomized SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coro-
ary Stent System in the Treatment of Patients With de Novo Native Coronary Artery Lesions) trials
ave evaluated the performance of EES, resulting in their approval by the Food and Drug Adminis-
ration, but data regarding unselected usage, including off-label indications are lacking.
ethods Consecutive patients treated with EES (either PROMUS, Boston Scientiﬁc Corp., Natick,
assachusetts, or XIENCE-V, Abbott Vascular Devices, Santa Clara, California) between October
006 and February 2008 were analyzed. End points were cardiac death, myocardial infarction (MI),
schemic-driven target lesion revascularization (TLR), stent thrombosis (ST), and major adverse car-
iac events (MACE) (a composite of cardiac death, MI, TLR) during follow-up.
esults We identiﬁed 345 patients (573 lesions) treated with EES. The majority of patients (71.9%)
ere treated for 1 off-label or untested indication. Clinical follow-up was completed in 99%. At a
edian follow-up of 378 days (interquartile range 334 to 473), MACE occurred in 36 (10.6%) pa-
ients, TLR in 27 (7.9%), MI in 7 (2.1%), and cardiac death in 7 (2.1%). Deﬁnite and probable ST was
bserved in 3 (0.9%) cases. Off-label EES implantation was not associated with a statistically signiﬁ-
ant increased risk of MACE (12.2% vs. 6.3%, p  0.17), TLR (9.3% vs. 4.2%, p  0.18), or ST (0.8%
s. 1.1%, p  1.0). On multivariable analysis, previous bypass surgery (p  0.002) and diabetes
p  0.03) were associated with MACE.
onclusions In unrestricted daily practice, EES were implanted predominantly for off-label indica-
ions and associated with a relative low rate of MACE and TLR. (J Am Coll Cardiol Intv 2009;2:
219–26) © 2009 by the American College of Cardiology Foundation
rom the *Interventional Cardiology Unit, San Raffaele Scientific Institute, Milan, Italy; †Interventional Cardiology Unit, EMO
entro Cuore Columbus, Milan, Italy; and the ‡Division of Cardiology, University of Cape Town, Cape Town, South Africa.
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1220he polymer-based everolimus-eluting stent (EES) (either
IENCE V, Abbott Vascular, Santa Clara, California; or
ROMUS, Boston Scientific Corp., Natick, Massachu-
etts) is a combination product composed of 3 major design
omponents: 1) a thin-strut (81 m), cobalt-chromium
lloy coronary stent; 2) a thin drug-carrying matrix, an
ltrapure copolymer composed of vinylidene fluoride and
exafluoropropylene monomers; and 3) everolimus, an an-
log of rapamycin, at a dose of 100 g/cm2 with 80% of the
rug eluted in 30 days (1,2). The polymer-based EES is
See page 1236
he most recent drug-eluting stent (DES) to undergo U.S.
ood and Drug Administration (FDA) approval. On the
asis of the positive outcomes of the SPIRIT (A Clinical
Evaluation of the XIENCE V
Everolimus Eluting Coronary
Stent System in the Treatment
of Patients With de Novo Na-
tive Coronary Artery Lesions)
family of randomized trials (2–6),
the FDA approved the EES for
U.S. commercial sale in July
2008 with the indication of “im-
proving coronary luminal diam-
eter in patients with symptom-
atic heart disease due to de novo
native coronary artery lesions
(length28 mm) with reference
vessel diameters of 2.5 mm to
4.25 mm” (1).
However, when DES are im-
planted in everyday clinical prac-
tice, they are often implanted for
off-label indications in complex
patients and lesions where the
benefit in reducing restenosis
nd repeat revascularization might be greater (7,8). As has
een seen with the first-generation DES, the clinical event
ates are often higher in real world registries compared with
hose seen in the randomized trials, and as a result, concerns
ave been raised about the efficacy and safety in off-label
ndications (9–12). Data regarding EES in these complex
atients and lesions are lacking. Thus we sought to evaluate
he clinical outcomes of unrestricted EES implantation in
aily practice.
ethods
ll consecutive patients successfully treated with only EES
mplantation at our center between October 2006 (when
ES became available in our institution) and February 2008
bbreviations and
cronyms
MS  bare-metal stent(s)
I  confidence interval
ES  drug-eluting stent(s)
ES  everolimus-eluting
tent(s)
DA  Food and Drug
dministration
VUS  intravascular
ltrasound
ACE  major adverse
ardiac events
I  myocardial infarction
T  stent thrombosis
LR  target lesion
evascularization
VR  target vessel
evascularizationin order to have a minimum of 1-year follow-up in most datients) were included in this retrospective analysis. Stent
election, although at the operator’s discretion, was carried
ut in an aleatory fashion during the study period. Selecting
n EES over another DES was performed without any
pecific preference and not based on patient risk or lesion
orphology. It is the usual practice in our institutions to
lternate the implantation of different types of DES. We
rovide a flow chart in Figure 1 describing the selection of
are-metal stents (BMS) and different DES at our institu-
ions during the period of this study. The only exclusion
riteria were a mixture of different types of DES or a
ixture of BMS and DES. Also patients undergoing
rimary angioplasty for ST-segment elevation myocardial
nfarction (MI) were excluded, because it is the practice of
ur institution not to implant a DES in these patients. All
atients provided informed consent for both the procedure
nd subsequent data collection.
All patients were pre-treated with aspirin and clopidogrel
r ticlopidine. A loading dose of 300 to 600 mg clopidogrel
as given to patients not treated in the prior 5 days. Aspirin
as continued indefinitely, and thienopyridine was pre-
cribed for at least 12 months. Glycoprotein IIb/IIIa inhib-
tors, interventional approaches, and intravascular ultra-
ound (IVUS) usage were at the operator’s discretion.
ngiographic follow-up was clinically driven or scheduled
t the operator’s discretion.
ata collection, end points, and deﬁnitions. Clinical
ollow-up was performed by telephone contact or office visit
t 1, 6, and 12 months after the index procedure. The
linical end points analyzed were periprocedural MI, death,
fter-discharge MI, stent thrombosis (ST), target vessel
evascularization (TVR), target lesion revascularization
TLR), and major adverse cardiac events (MACE). The
ACE was defined, as it was in the SPIRIT trials (2–5,13),
s a composite of cardiac death, MI, and TLR during the
ollow-up period, which were evaluated on a per-patient
asis. We also analyzed TLR separately on a per-lesion
asis. All deaths were considered cardiac unless otherwise
ocumented. We defined post-procedural non–Q-wave MI
s a creatinine kinase-myocardial band elevation of 3
imes the upper limit of normal (14). Creatinine kinase was
outinely measured after percutaneous coronary intervention
n all patients at both centers. Non-procedural or after-
ischarge MI was defined as an elevation of troponin above
he upper range limit in combination with at least 1 of the
ollowing: symptoms of ischemia, electrocardiography
hanges indicative of new ischemia, or the development of
athological Q waves on electrocardiography (14,15). We
efined TLR as repeat revascularization within the stent or
ithin the 5-mm borders proximal or distal to the stent
dge at the follow-up angiogram. The TLR was considered
o be ischemic-driven if associated with a positive functional
tudy result and/or ischemic symptoms and a target lesion
iameter stenosis of 50% by visual estimation or a target
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1221esion diameter stenosis of 70% with or without docu-
ented ischemia (2). These are exactly the same criteria
sed in the SPIRIT trials (2–5,13). We defined TVR as any
epeat revascularization of the target vessel. The ST was
efined as “acute” if within 24 h of the procedure, “subacute”
t 1 to 30 days, and “late” after 30 days. The definition of ST
as in accordance with the Academic Research Committee
efinitions of definite, probable, possible ST (15). In this
tudy we also analyzed the outcomes of EES when im-
lanted for “on-label” and “off-label” (or untested) indica-
ions. For the purpose of this study, an off-label indication
as defined as implantation of an EES in: 1) left main
oronary artery lesions; 2) chronic total occlusions; 3)
ifurcation lesions (i.e., main vessel treated by stent implan-
ation and side branch treated by angioplasty or stent
mplantation); 4) BMS or DES restenosis; 5) bypass graft
esions; 6) left ventricular ejection fraction 35%; 7) ostial
esions (either aorto-ostial or ostium of left anterior de-
cending or circumflex arteries); and 8) diffuse disease
efined as 2 or more overlapping stents with stented length
28 mm.
tatistical methods. Continuous variables are presented as
ean  SD or median with interquartile ranges, and
ategorical variables are presented as frequencies. The nor-
ality of the distribution of the continuous variables was
ested by the Kolmogorov-Smirnov goodness-of-fit test.
ontinuous variables were compared with independent
ample Student t or Mann-Whitney U test. Categorical
ariables were compared with chi-square statistic or Fisher
xact test when appropriate. Patients lost to follow-up in
Patients treated betwee
1533
BMS (25.6%)
392 patients/562 lesions
EES 345 (30.2%) SES 342 (3MIXED DES 20 (1.7%)
Figure 1. A Flow Chart Describing Stent Selection During the Study Period
BES  biolimus-eluting stent(s) (Nobori, Terumo Corporation, Tokyo, Japan); BM
stent(s) (either PROMUS, Boston Scientiﬁc Corp., Natick, Massachusetts, or XIEN
stent(s) (Cypher, Cordis, Johnson & Johnson Company, Warren, New Jersey); PE
Conor Medsystems, Menlo Park, California; and Inﬁnnium, Sahajanad Medical T
Resolute, Medtronic, Santa Rosa, California).hom no event had occurred before the follow-up windows bere not included in the denominator for calculations of
inary end points. We calculated 95% confidence intervals
CIs) for proportions by the Wilson method and the relative
isk by the exact method. Exploratory multivariable analysis
as performed to assess the impact of off-label EES usage
n the risk of MACE and TLR by logistic regression. The
nal model included variables associated at univariate analysis
ith MACE and TLR (all with a p value  0.1). The results
re reported as adjusted odds ratios (ORs) with associated 95%
I. Goodness of fit of the logistic regression model was
ssessed with the Hosmer-Lemeshow statistic. Survival curves
ith all available follow-up data were also constructed for
ime-to-event variables with Kaplan-Meier estimates. A p
alue  0.05 was considered statistically significant, and all
eported p values are 2-sided. Statistical analysis was per-
ormed with SPSS software (version 11.5, SPSS Inc.,
hicago, Illinois) and Confidence Interval Analysis.
esults
total of 345 patients and 573 lesions were treated with EES
uring the study period. The baseline clinical and lesion
haracteristics of the study population are summarized in Table
. According to the study definitions, EES were implanted for
n off-label indication in 337 (66.1%) lesions, with 248 (71.9%)
atients having 1 or more off-label lesion treated. The indica-
ions for off-label EES use are listed in Table 1. Clinical
ollow-up was available in 341 (98.8%) patients with a median
ollow-up time of 378 days (interquartile range 334 to 473).
he duration of clinical follow-up was not statistically different
ober 2006 and February 2008
5 lesions)
DES (74.4%)
1141 patients/2563 lesions
) ZES 71 (6.2%)PES 360 (31.6%) BES 3 (0.3%)
bare-metal stent(s); DES  drug-eluting stent(s); EES  everolimus-eluting
Abbott Vascular Devices, Santa Clara, California); SES  sirolimus-eluting
aclitaxel-eluting stent(s) (including Taxus, Boston Scientiﬁc Corp.; CoStar,
logies, India); ZES  zotarolimus-eluting stent(s) (Endeavor and Endeavorn Oct
 (312
0.0%
S 
CE-V,
S  p
echnoetween the 2 groups (p  0.41).
t
i
o
w
i
l
l
p
h
w
6
2
T
t
g
r
o
g
r
o
M
i
a
t
o
(
s
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 2 , N O . 1 2 , 2 0 0 9
D E C E M B E R 2 0 0 9 : 1 2 1 9 – 2 6
Latib et al.
Everolimus-Eluting Stents
1222The baseline procedural characteristics of the lesions
reated are summarized in Table 2, and the off-label
ndications for EES implantation are shown in Table 3. The
ff-label group presented with a more severe clinical profile
ith a higher frequency of diabetes mellitus (in particular
nsulin-requiring diabetes), unstable angina, and longer
esions. A larger number of stents and longer total stent
engths were implanted in the off-label group. The rate of
eriprocedural and in-hospital MI was nonsignificantly
igher with off-label EES use (7% vs. 0%; p  0.2). There
ere no cases of intra-procedural or acute ST.
Clinical follow-up outcome data are shown in Table 4. At
months, the overall rate of MACE was 4.7% (95% CI:
.9% to 7.5%), and TLR was 3.8% (95% CI: 2.2% to 6.4%).
Table 1. Baseline Characteristics of the Study Population
Overall
(n  345)
Age, yrs 64.5 9.6
Ejection fraction, % 54.5 9.1
Male 289 (83.8)
Hypertension 248 (71.9)
Hypercholesterolemia 250 (72.5)
Diabetes mellitus 100 (29.0)
Diet-controlled 6 (1.7)
Oral hypoglycemics 58 (16.8)
Insulin 36 (10.4)
Family history of coronary artery disease 146 (42.3)
Current smoker 38 (11.0)
Prior myocardial infarction 150 (43.5)
Prior percutaneous coronary
intervention
209 (60.6)
Prior coronary bypass surgery 73 (21.2)
Unstable angina 50 (14.5)
Multivessel disease 264 (76.5)
Premature dual antiplatelet therapy
discontinuation, months
0–6 2 (0.6)
6–12 11 (3.2)
Target vessel n  573
Left anterior descending 212 (37.0)
Left circumﬂex 136 (23.8)
Right coronary 144 (25.1)
Bypass graft 19 (3.3)
Venous 15 (2.6)
Left internal mammary 4 (0.7)
Left main 62 (10.8)
Target lesion n  573
Reference vessel diameter, mm 2.74 0.63
Minimal luminal diameter, mm 0.73 0.56
Diameter stenosis, % 74.50 18.36
Lesion length, mm 13.62 7.17
Data are presented as mean SD or n (%).here were no statistically significant differences in any of dhe adverse events between the on-label and off-label
roups. At a median follow-up time of 378 days, there
emained no significant difference in MACE between the
n-label (6.3%, 95% CI: 2.9% to 13.1%) and off-label
roups (12.2%, 95% CI: 8.4% to 17.0%; p  0.17). The
elative risk of MACE for the off-label compared with the
n-label group was 1.93 (95% CI: 0.83 to 4.49). A Kaplan-
eier plot of the cumulative incidence of MACE at 1 year
s shown in Figure 2. A multivariable model that included
ge, previous bypass surgery, hypertension, diabetes melli-
us, and treatment of a restenotic lesion showed that
ff-label EES implantation was not associated with MACE
OR: 1.38, 95% CI: 0.50 to 3.83; p 0.54). Previous bypass
urgery (OR: 3.23, 95% CI: 1.52 to 6.86, p  0.002) and
On-Label
(n  97)
Off-Label
(n  248) p Value
64.1 9.0 64.6 9.8 0.67
55.1 8.9 54.3 9.1 0.45
79 (81.4) 210 (84.7) 0.57
67 (69.1) 181 (73.0) 0.55
73 (75.3) 177 (71.4) 0.55
21 (21.6) 79 (31.9) 0.06
1 (1.0) 5 (2.0) 1.0
16 (16.5) 42 (16.9) 1.0
4 (4.1) 32 (12.9) 0.02
40 (41.2) 106 (42.7) 0.89
15 (15.5) 23 (9.3) 0.14
44 (45.4) 106 (42.7) 0.75
55 (56.7) 154 (62.1) 0.42
16 (16.5) 57 (23.0) 0.24
9 (9.3) 41 (16.5) 0.09
70 (72.2) 184 (74.2) 0.69
2 (2.1) 0 0.14
3 (3.1) 8 (3.2) 0.78
n  194 n  379
67 (34.5) 145 (38.3) 0.41
65 (33.5) 71 (18.7) 0.0001
62 (32.0) 82 (21.6) 0.008
0 19 (5.0) —
0 15 (3.9) —
0 4 (1.0) —
0 62 (16.4) —
n  194 n  379
2.60 0.52 2.79 0.68 0.004
0.73 0.40 0.71 0.62 0.67
71.98 14.55 76.24 19.67 0.02
12.40 5.75 14.51 7.87 0.01iabetes mellitus (OR: 2.33; 95% CI: 1.09 to 4.96, p 
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1223.03) were associated with MACE. The Hosmer-
emeshow statistic was not significant (p  0.89), confirm-
ng the goodness of fit of the logistic regression model. The
umerically albeit not significantly higher MACE in the
ff-label group was predominantly accounted for by a
umerically higher TLR rate in the off-label group (9.3% vs.
.2%; p 0.18). All-cause mortality, cardiac death, ST, and
onfatal MI were similar between the groups.
A lesion-based analysis revealed that there was a 3.6%
95% CI: 1.8% to 7.3%) TLR rate in on-label EES use
ompared with 6.1% (95% CI: 4.1% to 9.0%) in the off-label
roup (p 0.18). All repeat revascularization was ischemic-
riven. The variables entered into the multivariable model
Table 2. Baseline Procedural Characteristics
Variable
Lesions
(n  573)
Number of stents/lesion 1.16 0.43
Stent length/lesion, mm 25.69 13.11
Number of stents/patient 1.92 1.17
Range 1–8
Total stent length/patient, mm 42.45 30.02
Range 8–198
Maximum inﬂation pressure, atm 19.53 6.32
Minimum luminal diameter post, mm 2.89 0.55
Diameter stenosis post, % 10.01 7.10
Acute gain, mm 2.17 0.65
Rotational atherectomy 18 (3.1)
IVUS done 152 (26.5)
Glycoprotein IIb/IIIa inhibitors 38 (6.6%)
Intra-aortic balloon pump/patients 11/345 (3.2)
Data are presented as mean SD or n (%), unless otherwise specified.
IVUS intravascular ultrasound.
Table 3. Off-Label Indications for Everolimus-Eluting Stent Implantation
Lesion-Based
(n  379)
Patient-Based
(n  248)
Left main coronary artery, n (% of left main) 62 (16.4) 46 (18.5)
Distal 47 (75.8)
Ostial/body 15 (24.2)
Unprotected 48 (77.4)
Bifurcations, n (% of bifurcations) 172 (45.4) 92 (37.1)
Treated with 2 stents 71 (41.3)
Chronic total occlusion 69 (18.2) 52 (21.0)
Restenotic lesion, n (% of restenotic lesions) 101 (26.6) 81 (32.7)
DES restenosis 73 (72.3)
BMS restenosis 28 (27.7)
Bypass grafts 19 (5.0) 16 (6.5)
Ostial lesions 74 (19.5) 66 (26.6)
Diffuse disease 79 (20.8) 77 (31.0)
Multiple off-label 150 (39.6) 128 (51.6)
Data are presented as n (%).eBMS bare-metal stent(s); DES drug-eluting stent(s).or TLR were treatment of a restenotic lesion, IVUS usage,
tent length, and diabetes mellitus. This showed that
ff-label EES implantation was not associated with TLR
OR: 1.18, 95% CI: 0.44 to 3.19, p  0.74). Only diabetes
ellitus (OR: 3.39, 95% CI: 1.56 to 7.37, p  0.002) was
ssociated with TLR. The Hosmer and Lemeshow
oodness-of-fit test p value was 0.90, indicating the model
dequately fit the data.
At the last clinical follow-up contact, 3.8% (13) of
atients had prematurely discontinued dual antiplatelet
herapy before the prescribed 12 months. There were no
ifferences in the rates of ST between the groups. In the
otal study population, there were 3 (0.9%) cases of definite
T (2 late, and 1 subacute), no probable ST, and 8 cases of
ossible ST due to unexplained death after 30 days. All 3
ases of definite ST occurred in patients still taking dual
ntiplatelet therapy, and all of them survived the thrombotic
vent. There were 2 cases of definite ST in the off-label
roup. The first was a late ST at 262 days in an 82-year-old
an with a normal ejection fraction. He had undergone
ercutaneous coronary intervention of an ostial left anterior
escending artery lesion with a cross-over technique and
mplantation of a 3.5  23 mm EES from the distal left
ain to the left anterior descending artery, a provisional
pproach to the circumflex, and final kissing inflation to the
ifurcation. He presented with a non–ST-segment elevation
I; angiography demonstrated thrombus intrastent in the
istal left main involving the ostia of the circumflex and left
nterior descending arteries. He was treated with intrave-
ous glycoprotein IIb/IIIa inhibitors, balloon angioplasty,
nd BMS implantation. The second definite ST in the
ff-label group was in a 77-year-old woman with a normal
On-Label
(n  194)
Off-Label
(n  379) p Value
1.01 0.07 1.26 0.52 0.0001
21.35 5.83 28.62 15.29 0.0001
1.28 0.64 2.17 1.24 0.0001
1–5 1–8
26.53 16.33 48.67 31.83 0.0001
8–117 8–198
18.86 6.18 19.86 6.43 0.08
2.70 0.49 2.99 0.55 0.0001
10.64 7.59 9.74 6.94 0.22
1.98 0.55 2.26 0.68 0.0001
4 (2.1) 14 (3.7) 0.45
44 (22.7) 108 (28.5) 0.16
9 (4.7) 29 (7.7) 0.21
0 11/248 (4.4) 0.04jection fraction and diabetes treated with insulin. In the
i
c
d
w
i
p
c
u
t
D
T
u
f
l
a
t
S
w
w
i
s
a
f
w
s
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 2 , N O . 1 2 , 2 0 0 9
D E C E M B E R 2 0 0 9 : 1 2 1 9 – 2 6
Latib et al.
Everolimus-Eluting Stents
1224ndex procedure, she underwent stenting of an ostial cir-
umflex lesion with a 3.5  12 mm EES. She presented 27
ays later with a subacute ST and acute MI that was treated
ith repeat BMS implantation. The only case of definite ST
n the on-label group occurred in a 62-year-old man who
resented at 73 days with a late ST after having a mid-
ircumflex lesion treated with a 3  23 mm EES. He
nderwent primary angioplasty with repeat DES implanta-
ion at another institution.
iscussion
he main findings of this real-world registry are: 1) in
nrestricted daily practice, EES were implanted predominantly
Table 4. Clinical Outcomes In-Hospital, at 6-Month
378 Days
Overall
(n  341)
In-hospital events
Periprocedural MI 7 (2.0)
Death 0
Acute stent thrombosis 0
6-month events*
MACE 16 (4.7)
Total death 3 (0.9)
Cardiac death 2 (0.6)
MI 3 (0.9)
ARC stent thrombosis
Deﬁnite 2 (0.6)
Probable 0
Possible 2 (0.6)
Any 4 (1.2)
TLR (per-patient) 13 (3.8)
TLR (per-lesion) 15/569 (2.6)
TVR (per-patient) 18 (5.3)
TVR (per-lesion) 25/569 (4.4)
Cumulative*
MACE 36 (10.6)
Total death 8 (2.3)
Cardiac death 7 (2.1)
MI 7 (2.1)
ARC stent thrombosis
Deﬁnite 3(0.9)
Probable 0
Possible 5 (1.5)
Any 8 (2.3)
TLR (per-patient) 27 (7.9)
TLR (per-lesion) 30/569 (5.3)
TVR (per-patient) 38 (11.1)
TVR (per-lesion) 55/569 (9.7)
Data are presented as n (%). *Except periprocedural myocardial infarc
ARC  Academic Research Consortium; MACE  major adverse
revascularization.or off-label indications and were associated with a relatively low rate of ischemic-driven TLR and MACE during short-
nd medium-term follow-up; 2) although MACE and TLR in
his complex cohort were slightly higher than those seen in the
PIRIT randomized trials (2–6), the results of on-label use
ere comparable; 3) the rates of cardiac death, MI, and ST
ere not statistically different for on-label and off-label EES
mplantation; 4) on multivariable analysis, previous bypass
urgery and diabetes were associated with MACE and diabetes
lso with TLR, but off-label EES implantation was not a risk
actor for either MACE or TLR; and 5) even though TLR
as twice as frequent in off-label patients, it did not reach
tatistical significance.
In this study the majority of patients had an off-label
During the Total Follow-Up Period of a Median of
On-Label
(n  95)
Off-Label
(n  246) p Value
0 7 (2.8) 0.20
0 0
0 0
3 (3.2) 13 (5.3) 0.57
1 (1.1) 2 (0.8) 1.0
1 (1.1) 1 (0.4) 0.48
1 (1.1) 2 (0.8) 1.0
1 (0.8) 1 (0.4) 0.48
0 0
1 (1.1) 1 (0.4)0 0.48
2 (2.1) 2 (0.8) 0.31
2 (2.1) 11 (4.5) 0.53
4/192 (2.1) 11/377 (2.9) 0.78
3 (3.2) 15 (6.1) 0.42
6/192 (3.1) 19/377 (5.0) 0.39
6 (6.3) 30 (12.2) 0.17
2 (2.1) 6 (2.4) 1.0
2 (2.1) 5 (2.0) 1.0
1 (1.1) 6 (2.4) 0.68
1(1.1) 2(0.8) 1.0
0 0
2 (2.1) 3 (1.2) 0.62
3 (3.2) 5 (2.0) 0.69
4 (4.2) 23 (9.3) 0.18
7/192 (3.6) 23/377 (6.1) 0.24
8 (8.4) 30 (12.2) 0.44
7/192 (8.9) 38/377 (10.1) 0.76
I).
events; TLR  target lesion revascularization; TVR  target vessels, and
1
tion (M
cardiacesion treated with an EES—contrary to most randomized
t
t
c
c
w
S
o
t
a
q
a
e
c
(
i
a
C
g
s
m
i
I
l
a
p
v
g
e
o
0
l
c
a
d
b
p
m
i
i
i
e
b
c
o
t
a
r
t
i
b
c
a
p
g
b
e
s
n
g
m
a
i
e
l
D
p
t
S
e
d
o
r
S
o
p
o
e
p
t
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 2 , N O . 1 2 , 2 0 0 9 Latib et al.
D E C E M B E R 2 0 0 9 : 1 2 1 9 – 2 6 Everolimus-Eluting Stents
1225rials—with one-half of the off-label patients having more
han 1 off-label lesion treated. However, despite this in-
reased complexity of the patients and lesions treated, the
umulative 10.6% MACE and 7.9% TLR rates in this study
ere not markedly different from the 12-month rates in the
PIRIT III trial of 6.0% and 3.8% (2). In fact, when
n-label lesions such as those enrolled in the SPIRIT III
rial were considered, the rates of MACE (6.3% vs. 6.0%)
nd TLR (4.2% vs. 3.8%) were almost identical. The
uestion of whether off-label DES implantation is associ-
ted with worse outcomes in particular with regard to hard
nd points such as death and MI has been an area of great
oncern for patients, care-givers, and health authorities
1,7,8,16–19). Thus we performed a comparison of EES
mplanted for on-label (i.e., Food and Drug Administration-
pproved) indications with off-label and untested usage.
onsidering the complexity of the lesions in the off-label
roup (e.g., left main, diffuse disease, chronic total occlu-
ions, and bifurcations), the procedures performed were
ore complex with more and longer stents implanted,
ncreased intra-aortic balloon pump support, and greater
VUS use. We should also point out that the finding of a
arger reference vessel diameter in the off-label group,
lthough seemingly counterintuitive, is most likely due to
ercutaneous coronary intervention on vessels with a larger
essel diameter, such as the left main and saphenous vein
rafts. Indeed, when we excluded these lesions, the refer-
No. at risk
Off-Label 246 241 231 211 150
On-Label 95 93 91 86 61
0
5
10
15
20
Off-Label
On-Label
36590 180 2700
Time (days)
P
er
ce
n
t
Log rank p-value 0.1636 
HR: 1.70 (0.81 to 3.58)
Figure 2. Time-to-Event Curves for MACE Up to 1 Year
Time-to-event curves for major adverse cardiac events (MACE) up to 1 year
among patients undergoing everolimus-eluting stent implantation for on-
label and off-label indications. Event rates presented here were calculated
by Kaplan-Meier methods and compared with the log-rank test and differ
slightly from those in the results and Table 4, which were calculated as cat-
egorical variables and compared with the Fisher exact test. The number of
patients at risk for each follow-up period is given below each graph. HR 
hazard ratio.nce vessel diameter was similar between the on-label and hff-label groups (2.60  0.52 mm vs. 2.69  0.61 mm, p 
.13). The factors that probably contribute most to the
arger acute gain in the off-label group were the inclusion of
hronic total occlusions; the slightly higher use of IVUS;
nd that many off-label lesions were in the context of more
iffuse coronary disease, a situation where the mismatch
etween angiography and IVUS vessel size is larger com-
ared with more simple lesions. This situation will give
ore advantage in terms of acute gain when IVUS is used
n off-label compared with on-label lesions. Despite the
ncreased complexity of the patients, lesions treated, and
nterventional procedure, the rate of in-hospital adverse
vents was not statistically different between the 2 groups,
ut there were numerically more periprocedural MI. The
umulative TLR rate, which was numerically higher in the
ff-label group (9.3% vs. 4.2%), can be explained by the fact
hat these patients had a greater number of lesions treated
nd most of these were complex, justifying a higher rate of
e-intervention (20). That these differences were not statis-
ically significant is likely a consequence of the overall
nsufficient number of patients evaluated. Furthermore, we
elieve that the TLR rate in this complex cohort is realistic,
onsidering that we do not currently perform routine
ngiographic follow-up, which occurred only in 45% of
atients.
Because the off-label indications are known to form a
roup at high risk of restenosis that might have greater
enefit from DES, a higher TLR rate might be acceptable,
specially because the rates of death and MI were not
tatistically higher. Furthermore, off-label EES usage was
ot associated with MACE on multivariable analysis, sug-
esting that the implantation of EES in off-label lesions
ight be acceptable and without incremental risk.
It has been proposed that EES might have a theoretical
dvantage over first-generation DES with regard to safety,
n that the thin strut design might result in more rapid stent
ndothelialization (13,21). Indeed the rate of ST is much
ess than we previously reported with the first-generation
ES (7). Furthermore, the 0.9% rate of definite and
robable ST in this study of complex lesions is very similar
o that reported in on-labels lesions at 12 months in the
PIRIT III trial (1.1%) (2). The low rate of ST might be
xplained by the high compliance and extended duration of
ual antiplatelet therapy. However, it is reassuring that
ff-label EES implantation was not associated with a higher
isk of ST.
tudy limitations. This study suffers the obvious limitations
f observational nonrandomized registries. However, it does
rovide important complementary information about the
utcomes in real-world patients and lesions that were
xcluded from the randomized trials. The study is under-
owered to permit any strong conclusions to be drawn from
he subgroup analyses, which should be considered
ypothesis-generating. Furthermore, the small number of
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1226vents limits the ability to control for all differences among
he subgroups without some over-fitting of the multivari-
ble model. Similarly, the relatively small overall sample size
rohibits any judgment to be made with regard to ST as a
afety parameter, because this is a very rare event. Longer-
erm follow-up is required, because the incremental risk of
T with DES might emerge beyond 1 year (22). However,
n the SPIRIT III trial, there were fewer ST events after 1
ear in patients treated with EES rather than paclitaxel-
luting stents (13). The lack of routine angiographic
ollow-up precludes any comments about the antirestenotic
fficacy of EES in complex lesions. However, in this clinical
tudy all TLR was ischemic-driven, and thus the effect of an
verzealous oculostenotic reflex might be limited. Despite
hese shortcomings, these initial observations do provide an
mportant insight into the clinical spectrum and clinical
utcomes of patients and lesions currently being treated
ith this second-generation DES.
onclusions
n unrestricted daily practice, EES were implanted predom-
nantly for off-label and untested indications and associated
ith a relatively low rate of MACE and ischemic-driven
LR. However, longer-term data are needed to assess the
afety of this new platform in complex lesions.
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